The future of blood-based biomarkers for Alzheimer's disease

Kim Henriksen, Sid E. O'Bryant, Harald Hampel, John Q. Trojanowski, Thomas J. Montine, Andreas Jeromin, Kaj Blennow, Anders Lönneborg, Tony Wyss-Coray, Holly Soares, Chantal Bazenet, Magnus Sjögren, William Hu, Simon Lovestone, Morten A. Karsdal, Michael W. Weiner

Research output: Contribution to journalReview article

138 Citations (Scopus)

Abstract

Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease progression or treatment response, and most are measured in cerebrospinal fluid, which limits their applicability. With these aspects in mind, the aim of this article is to underscore the concerted efforts of the Blood-Based Biomarker Interest Group, an international working group of experts in the field. The points addressed include: (1) the major challenges in the development of blood-based biomarkers of AD, including patient heterogeneity, inclusion of the "right" control population, and the blood-brain barrier; (2) the need for a clear definition of the purpose of the individual markers (e.g., prognostic, diagnostic, or monitoring therapeutic efficacy); (3) a critical evaluation of the ongoing biomarker approaches; and (4) highlighting the need for standardization of preanalytical variables and analytical methodologies used by the field.

Original languageEnglish
Pages (from-to)115-131
Number of pages17
JournalAlzheimer's and Dementia
Volume10
Issue number1
DOIs
StatePublished - 1 Jan 2014

Fingerprint

Alzheimer Disease
Biomarkers
Public Opinion
Blood-Brain Barrier
Cerebrospinal Fluid
Disease Progression
Therapeutics
Population

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Blood
  • Plasma
  • Serum

Cite this

Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., ... Weiner, M. W. (2014). The future of blood-based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 10(1), 115-131. https://doi.org/10.1016/j.jalz.2013.01.013
Henriksen, Kim ; O'Bryant, Sid E. ; Hampel, Harald ; Trojanowski, John Q. ; Montine, Thomas J. ; Jeromin, Andreas ; Blennow, Kaj ; Lönneborg, Anders ; Wyss-Coray, Tony ; Soares, Holly ; Bazenet, Chantal ; Sjögren, Magnus ; Hu, William ; Lovestone, Simon ; Karsdal, Morten A. ; Weiner, Michael W. / The future of blood-based biomarkers for Alzheimer's disease. In: Alzheimer's and Dementia. 2014 ; Vol. 10, No. 1. pp. 115-131.
@article{1dca9c660164459981c1834d53cf1b2b,
title = "The future of blood-based biomarkers for Alzheimer's disease",
abstract = "Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease progression or treatment response, and most are measured in cerebrospinal fluid, which limits their applicability. With these aspects in mind, the aim of this article is to underscore the concerted efforts of the Blood-Based Biomarker Interest Group, an international working group of experts in the field. The points addressed include: (1) the major challenges in the development of blood-based biomarkers of AD, including patient heterogeneity, inclusion of the {"}right{"} control population, and the blood-brain barrier; (2) the need for a clear definition of the purpose of the individual markers (e.g., prognostic, diagnostic, or monitoring therapeutic efficacy); (3) a critical evaluation of the ongoing biomarker approaches; and (4) highlighting the need for standardization of preanalytical variables and analytical methodologies used by the field.",
keywords = "Alzheimer's disease, Biomarkers, Blood, Plasma, Serum",
author = "Kim Henriksen and O'Bryant, {Sid E.} and Harald Hampel and Trojanowski, {John Q.} and Montine, {Thomas J.} and Andreas Jeromin and Kaj Blennow and Anders L{\"o}nneborg and Tony Wyss-Coray and Holly Soares and Chantal Bazenet and Magnus Sj{\"o}gren and William Hu and Simon Lovestone and Karsdal, {Morten A.} and Weiner, {Michael W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jalz.2013.01.013",
language = "English",
volume = "10",
pages = "115--131",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",

}

Henriksen, K, O'Bryant, SE, Hampel, H, Trojanowski, JQ, Montine, TJ, Jeromin, A, Blennow, K, Lönneborg, A, Wyss-Coray, T, Soares, H, Bazenet, C, Sjögren, M, Hu, W, Lovestone, S, Karsdal, MA & Weiner, MW 2014, 'The future of blood-based biomarkers for Alzheimer's disease', Alzheimer's and Dementia, vol. 10, no. 1, pp. 115-131. https://doi.org/10.1016/j.jalz.2013.01.013

The future of blood-based biomarkers for Alzheimer's disease. / Henriksen, Kim; O'Bryant, Sid E.; Hampel, Harald; Trojanowski, John Q.; Montine, Thomas J.; Jeromin, Andreas; Blennow, Kaj; Lönneborg, Anders; Wyss-Coray, Tony; Soares, Holly; Bazenet, Chantal; Sjögren, Magnus; Hu, William; Lovestone, Simon; Karsdal, Morten A.; Weiner, Michael W.

In: Alzheimer's and Dementia, Vol. 10, No. 1, 01.01.2014, p. 115-131.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The future of blood-based biomarkers for Alzheimer's disease

AU - Henriksen, Kim

AU - O'Bryant, Sid E.

AU - Hampel, Harald

AU - Trojanowski, John Q.

AU - Montine, Thomas J.

AU - Jeromin, Andreas

AU - Blennow, Kaj

AU - Lönneborg, Anders

AU - Wyss-Coray, Tony

AU - Soares, Holly

AU - Bazenet, Chantal

AU - Sjögren, Magnus

AU - Hu, William

AU - Lovestone, Simon

AU - Karsdal, Morten A.

AU - Weiner, Michael W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease progression or treatment response, and most are measured in cerebrospinal fluid, which limits their applicability. With these aspects in mind, the aim of this article is to underscore the concerted efforts of the Blood-Based Biomarker Interest Group, an international working group of experts in the field. The points addressed include: (1) the major challenges in the development of blood-based biomarkers of AD, including patient heterogeneity, inclusion of the "right" control population, and the blood-brain barrier; (2) the need for a clear definition of the purpose of the individual markers (e.g., prognostic, diagnostic, or monitoring therapeutic efficacy); (3) a critical evaluation of the ongoing biomarker approaches; and (4) highlighting the need for standardization of preanalytical variables and analytical methodologies used by the field.

AB - Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease progression or treatment response, and most are measured in cerebrospinal fluid, which limits their applicability. With these aspects in mind, the aim of this article is to underscore the concerted efforts of the Blood-Based Biomarker Interest Group, an international working group of experts in the field. The points addressed include: (1) the major challenges in the development of blood-based biomarkers of AD, including patient heterogeneity, inclusion of the "right" control population, and the blood-brain barrier; (2) the need for a clear definition of the purpose of the individual markers (e.g., prognostic, diagnostic, or monitoring therapeutic efficacy); (3) a critical evaluation of the ongoing biomarker approaches; and (4) highlighting the need for standardization of preanalytical variables and analytical methodologies used by the field.

KW - Alzheimer's disease

KW - Biomarkers

KW - Blood

KW - Plasma

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=84891112523&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2013.01.013

DO - 10.1016/j.jalz.2013.01.013

M3 - Review article

C2 - 23850333

AN - SCOPUS:84891112523

VL - 10

SP - 115

EP - 131

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -

Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimer's and Dementia. 2014 Jan 1;10(1):115-131. https://doi.org/10.1016/j.jalz.2013.01.013